Thelansis

Resistant Hypertension (RH) Market Outlook Thelansis’s “Resistant Hypertension (RH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Resistant Hypertension (RH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the mar...

  Resistant hypertension (RH) is characterized by persistently elevated blood pressure (BP) despite the concurrent administration of three antihypertensive drug classes. These typically include a long-acting calcium channel blocker, a renin-angiotensin system blocker (either an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker), and a diuretic. Additionally, RH encompasses cases where BP reaches target values despite the use of four or more antihypertensive medications. Diagnosis necessitates confirmation of medication adherence and the exclusion of the "white-coat effect," where office BP surpasses the goal but out-of-office BP remains within the target range. Patients with RH face elevated risks of various adverse outcomes. Specifically, they exhibit a 32% heightened risk of developing end-stage renal disease, a 24% increased risk of experiencing an ischemic heart event, a 46% higher likelihood of heart failure, a 14% elevated risk of stroke, and a 6...